Handelsbanken Fonder AB Sells 446,938 Shares of Bristol Myers Squibb Company $BMY

Handelsbanken Fonder AB lowered its position in Bristol Myers Squibb Company (NYSE:BMY) by 32.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 910,107 shares of the biopharmaceutical company’s stock after selling 446,938 shares during the period. Handelsbanken Fonder AB’s holdings in Bristol Myers Squibb were worth $52,440,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Bayban bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb during the fourth quarter worth $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst earnings estimates increased: Erste Group Bank raised its FY2026 EPS forecast for BMY to $6.96 from $6.34, matching the broader consensus, and lifted its FY2027 estimate to $6.51 from $6.10. The revisions suggest improving confidence in the company’s earnings outlook. Bristol Myers Squibb earnings estimate revisions
• Positive Sentiment: $2.3 billion Houston manufacturing campus: BMY plans to build an approximately 600,000-square-foot advanced manufacturing and life sciences facility at Generation Park in Houston. The project is expected to create about 500 permanent jobs and roughly 2,000 construction jobs, expanding the company’s U.S. production capacity and supporting its previously announced $40 billion domestic investment commitment. Bristol Myers to build $2.3 billion manufacturing site in Houston
• Neutral Sentiment: Broker sentiment remains favorable but not strongly bullish: BMY continues to carry an average “Moderate Buy” recommendation. Recent commentary highlights the company’s growth portfolio and pipeline, but also cautions that generic competition and the stock’s prior gains could limit near-term upside. Bristol Myers Squibb receives Moderate Buy recommendation
• Negative Sentiment: Merger speculation is unconfirmed: Reports that BMY held merger discussions with AstraZeneca helped send AZN sharply lower, but neither company confirmed the talks. The lack of confirmation and skepticism from Wall Street may weigh on BMY by raising questions about deal costs, integration risks and strategic priorities, even though a combination would create one of the world’s largest drugmakers. AstraZeneca versus Bristol Myers Squibb merger speculation

Analysts Set New Price Targets

Several brokerages have commented on BMY. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Citigroup reiterated a “neutral” rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. TD Cowen started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating for the company. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings raised Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $63.66 on Wednesday. The company has a market capitalization of $130.05 billion, a price-to-earnings ratio of 14.02, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.10. The firm’s 50-day moving average is $59.09 and its 200 day moving average is $58.80. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter last year, the firm earned $1.46 earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.96 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.